Glow BPC-70 – Research Compound Profile

Glow BPC-70 – Research Compound Profile

Category: Dermatological Research | Molecular Type: Multi-Peptide Complex (Copper Peptide + BPC-157 Fragment + Growth Factor Peptides) | Research Status: Proprietary Blend — Individual Components Clinically Studied

This page compiles published research data for qualified researchers. Glow BPC-70 is sold exclusively as a research compound and is not approved for human use. The proprietary blend has not been independently evaluated in clinical trials; research findings below pertain to the individual component peptides (GHK-Cu, BPC-157).

Purchase for Research →

Molecular Overview

Glow BPC-70 is a proprietary multi-peptide complex designed for dermatological research applications. It combines GHK-Cu (glycyl-L-histidyl-L-lysine:copper(II) complex), a naturally occurring human tripeptide first identified in 1973, with BPC-157 fragments (body protective compound, pentadecapeptide) and complementary bioactive peptides. The formulation targets transdermal delivery with an intended 70% skin-penetration bioavailability [1][2].

GHK-Cu is present endogenously in human blood plasma at approximately 200 ng/mL in young adults, with levels declining to approximately 80 ng/mL by age 60 [1]. As a tripeptide-copper complex, it has a molecular weight of approximately 403.9 Da. BPC-157 is a synthetic pentadecapeptide (molecular weight ~1419 Da) derived from a sequence found in human gastric juice. Both components have been extensively studied individually in preclinical and limited clinical settings for their roles in tissue repair, collagen synthesis, and angiogenesis.

The formulation is supplied in lyophilized form at 50 mg per vial and is intended exclusively for topical and transdermal research applications, not for injection, oral consumption, or mucosal administration.

Mechanism of Action

Glow BPC-70 leverages a multi-pathway dermal regeneration strategy through three categories of bioactive peptides, each contributing a distinct molecular mechanism.

GHK-Cu — Collagen Synthesis and Genomic Modulation

GHK-Cu functions as a broad-spectrum genomic modulator. Research by Pickart and Margolina (2018) documented that this tripeptide-copper complex is capable of resetting the expression of over 4,000 human genes — stimulating 59% and suppressing 41% — including those governing collagen synthesis, glycosaminoglycan production, metalloproteinase regulation, and antioxidant defense [3].

At the cellular level, GHK-Cu binds copper(II) ions and delivers them to fibroblasts. Maquart et al. (1988) demonstrated in fibroblast cultures that the GHK-Cu complex activates collagen I and III synthesis, elastin production, proteoglycan deposition, and decorin expression in the extracellular matrix [7]. The copper moiety also serves as a cofactor for lysyl oxidase, the enzyme responsible for crosslinking collagen and elastin fibers into their mature, functional architecture.

Additionally, GHK-Cu has been observed to suppress NFκB-driven inflammatory cascades, reduce pro-inflammatory IL-6 and TNF-α, and activate the ubiquitin-proteasome system to clear damaged proteins — a process that naturally declines with aging [1].

BPC-157 Fragment — Angiogenesis and Growth Factor Signaling

The BPC-157 fragment component contributes through VEGF (vascular endothelial growth factor) upregulation and ERK1/2 signaling pathway activation. Huang et al. (2015) reported that BPC-157 promoted VEGF-a expression in wounded skin tissues, accelerated endothelial cell proliferation and migration, and stimulated vascular tube formation — the process by which new capillary networks develop to supply nutrients and oxygen to regenerating tissue [2].

The same study documented that BPC-157 upregulated transcription factors c-Fos, c-Jun, and Egr-1 by 4.99×, 7.05×, and 3.70× respectively, which are key mitogenic pathway drivers for fibroblast proliferation and wound remodeling [2].

Transdermal Delivery Considerations

Research on GHK-Cu skin penetration by Mazurowska and Mojski (2008) confirmed that the tripeptide-copper complex can cross the stratum corneum barrier, with penetration studies showing measurable delivery into deeper dermal layers [9]. A complementary study by the same authors (2007) examined the mechanism of GHK-Cu complex transport through a model membrane of the stratum corneum using ESI-MS analysis [10]. Hostynek et al. (2010) further characterized in vitro skin retention and penetration of the copper tripeptide as a function of skin layer [18]. Badhe et al. (2015) investigated microneedle-mediated delivery as an approach to enhance copper peptide transport through skin barriers [17].

Published Research Parameters

The following table summarizes experimental conditions, models, and observations reported in peer-reviewed publications concerning the individual component peptides of Glow BPC-70. These reflect published research protocols and are not recommendations for any use.

Stability & Storage Characteristics

The following stability data are derived from published peptide handling literature and manufacturer guidelines:

• Lyophilized form: Peptides in lyophilized form demonstrate optimal long-term stability when stored at −20 °C or below. Refrigeration at 2–8 °C is documented as acceptable for shorter durations (weeks). Sealed containers with desiccant are recommended to prevent moisture absorption [4].
• Reconstituted solution: Published guidelines indicate reconstituted peptide solutions should be maintained at 2–8 °C and are generally considered stable for up to 28 days under proper storage conditions. Freeze-thaw cycles are documented to degrade copper-peptide complexes and should be avoided [4].
• Light sensitivity: GHK-Cu is photosensitive; UV exposure can accelerate copper-mediated oxidation reactions. Published protocols recommend amber containers or foil-wrapped storage to minimize photodegradation [1].
• Solution appearance: Normal GHK-Cu-containing solutions range from clear to pale blue. Discoloration (dark green or brown), cloudiness, or visible particulate matter may indicate degradation.
• Formulation note: This compound is formulated for topical/transdermal research application only and is not intended for injection, oral consumption, or mucosal administration.

Key Published Research Findings

The following findings are derived from published peer-reviewed literature on the individual component peptides (GHK-Cu, BPC-157).

• Collagen synthesis stimulation: In a 1998 study published in Disease Management and Clinical Outcomes, Abdulghani et al. observed that topical copper-binding peptide cream improved collagen production in the majority of treated subjects over 12 weeks, with a more favorable ultrastructural response than the vitamin C and retinoic acid (tretinoin) comparators evaluated in the same study [11].

• Wrinkle parameter reduction: In a 2016 randomized, double-blind study published in the Journal of Aging Science, Badenhorst et al. reported that GHK-Cu serum produced a statistically significant reduction in wrinkle volume and wrinkle depth compared to control serum over 8 weeks [5].

• Skin density and firmness improvements: In a study presented at the American Academy of Dermatology 60th Annual Meeting (2002), Leyden et al. evaluated a copper peptide–containing facial cream in 71 women over 12 weeks. The study documented increased skin density, improved thickness, reduced laxity, enhanced clarity, and decreased fine lines and wrinkle depth [12].

• Wound healing acceleration: In a 2015 Drug Design, Development and Therapy study, Huang et al. demonstrated that BPC-157 at concentrations as low as 200 ng/mL achieved approximately 80% wound closure by day 18 in rat alkali-burn models, comparable to bFGF-positive controls. The peptide promoted VEGF-a expression in wounded skin tissue and stimulated endothelial tube formation in vitro in a dose-dependent manner [2].

• Topical BPC-157 in burn models: In a 2001 study published in Burns, Mikus et al. observed that BPC-157 cream formulations applied topically to mouse burn wound models demonstrated enhanced granulation tissue formation, accelerated reepithelialization, and significantly higher collagen deposition compared to untreated controls [8].

• Angiogenic signaling: Huang et al. (2015) further documented that BPC-157 upregulated transcription factors c-Fos, c-Jun, and Egr-1 by 4.99×, 7.05×, and 3.70× respectively in endothelial cell models, identifying key mitogenic signaling pathways involved in fibroblast proliferation and wound remodeling [2].

• Antioxidant activity: In a 2007 study published in Chemical Research in Toxicology, Beretta et al. demonstrated that GHK blocked Cu²⁺-dependent LDL oxidation at 100% efficiency — compared to only 20% for superoxide dismutase (SOD). GHK also scavenged reactive carbonyl species (acrolein, 4-hydroxynonenal) that accumulate from UV-induced oxidative damage [13].

• Genomic modulation breadth: Pickart et al. (2015) characterized GHK as capable of modulating the expression of over 4,000 human genes involved in collagen synthesis, glycosaminoglycan production, metalloproteinase regulation, and antioxidant defense, positioning it as a broad-spectrum genomic modulator in dermal tissue contexts [3].

• Transdermal penetration: Mazurowska and Mojski (2008) confirmed measurable penetration of the GHK-Cu complex through the stratum corneum barrier into deeper dermal layers, supporting the feasibility of topical delivery [9]. Enhanced delivery via microneedle-mediated approaches was further explored by Badhe et al. (2015) [17].

Safety Profile in Published Literature

Toxicology and Tolerability Data

• GHK-Cu long-term safety: GHK-Cu has been incorporated into cosmetic formulations for over four decades. Pickart and Margolina (2018) noted no documented systemic adverse effects in the published literature [1].
• BPC-157 safety margin: Sikiric et al. (2021) reported in a Frontiers in Pharmacology review that BPC-157 demonstrated a wide safety margin across multiple preclinical studies, with no lethal dose (LD1) identified in toxicology testing [15].
• Copper compound dermal toxicity: A 2016 study in Scientific Reports investigated potential skin toxicity caused by certain copper compounds using selected biomarkers, noting that specific copper formulations and concentrations warrant careful evaluation in dermal applications [14].
• Photosensitivity considerations: Published literature notes that copper-peptide complexes may marginally increase skin photosensitivity, and researchers studying topical GHK-Cu applications have incorporated UV protection protocols into study designs [1].

Limitations of Current Evidence

• Published safety and efficacy data pertain to the individual component peptides (GHK-Cu and BPC-157) studied separately. The specific proprietary Glow BPC-70 blend has not been independently evaluated in clinical trials.
• Most BPC-157 wound healing data are derived from rodent models; human clinical data for BPC-157 in dermatological applications remain limited.
• Long-term safety data (beyond 12 weeks) for topical copper peptide formulations are sparse in the peer-reviewed literature.

Regulatory Status

• FDA approval: Glow BPC-70 is not approved by the FDA for human use. Neither GHK-Cu nor BPC-157 has received FDA approval as a therapeutic agent.
• GHK-Cu regulatory context: GHK-Cu is widely used as a cosmetic ingredient and is present in numerous commercially available skincare products, though this does not constitute FDA drug approval.
• BPC-157 regulatory context: BPC-157 remains an investigational compound. The FDA has not approved BPC-157 for any therapeutic indication.
• Research use only: This compound is sold exclusively for research purposes and must not be used for human consumption, self-administration, or any therapeutic application. All research must comply with applicable laws, regulations, and institutional guidelines.

References

1. International Journal of Molecular Sciences (2018) — Pickart L, Margolina A. Regenerative and Protective Actions of the GHK-Cu Peptide in the Light of the New Gene Data. View Source

2. Drug Design, Development and Therapy (2015) — Huang T, Zhang K, Sun L, et al. Body Protective Compound-157 Enhances Alkali-Burn Wound Healing In Vivo and Promotes Proliferation, Migration, and Angiogenesis In Vitro. View Source

3. BioMed Research International (2015) — Pickart L, Vasquez-Soltero JM, Margolina A. GHK Peptide as a Natural Modulator of Multiple Cellular Pathways in Skin Regeneration. View Source

4. Bachem Peptide Technical Guide (2023) — Handling and Storage Guidelines for Peptides. View Source

5. Journal of Aging Science (2016) — Badenhorst T, Svirskis D, Merrilees M, Bolke L, Wu Z. Effects of GHK-Cu on MMP and TIMP Expression, Collagen and Elastin Production, and Facial Wrinkle Parameters. View Source

6. Journal of Biomaterials Science, Polymer Edition (2008) — Pickart L. The Human Tri-Peptide GHK and Tissue Remodeling. View Source

7. FEBS Letters (1988) — Maquart FX, Pickart L, Laurent M, Gillery P, Monboisse JC, Borel JP. Stimulation of Collagen Synthesis in Fibroblast Cultures by the Tripeptide-Copper Complex Glycyl-L-Histidyl-L-Lysine-Cu2+. View Source

8. Burns (2001) — Mikus D, Sikiric P, Seiwerth S, et al. Pentadecapeptide BPC 157 Cream Improves Burn-Wound Healing and Attenuates Burn-Gastric Lesions in Mice. View Source

9. Journal of Cosmetic Science (2008) — Mazurowska L, Mojski M. Biological Activities of Selected Peptides: Skin Penetration Ability of Copper Complexes with Peptides. View Source

10. Talanta (2007) — Mazurowska L, Mojski M. ESI-MS Study of the Mechanism of GHK-Cu Complex Transport Through Model Membrane of Stratum Corneum. View Source

11. Disease Management and Clinical Outcomes (1998) — Abdulghani A, Sherr A, Shirin S, et al. Effects of Topical Creams Containing Vitamin C, a Copper-Binding Peptide Cream and Melatonin Compared with Tretinoin on the Ultrastructure of Normal Skin. View Source

12. American Academy of Dermatology 60th Annual Meeting (2002) — Leyden J, Stephens T, Finkey M, Appa Y, Barkovic S. Skin Care Benefits of Copper Peptide Containing Facial Cream. View Source

13. Chemical Research in Toxicology (2007) — Beretta G, Artali R, Regazzoni L, Panigati M, Facino RM. Glycyl-Histidyl-Lysine (GHK) Is a Quencher of α,β-4-Hydroxy-trans-2-Nonenal: A Comparison with Carnosine. View Source

14. Scientific Reports (2016) — Selected Biomarkers Revealed Potential Skin Toxicity Caused by Certain Copper Compounds. View Source

15. Frontiers in Pharmacology (2021) — Sikiric P, Hrelec M, Rucman R, et al. Stable Gastric Pentadecapeptide BPC 157 and Wound Healing. View Source

16. American Journal of Clinical Nutrition (2001) — Boyera N, Galey I, Bernard BA. Effect of Vitamin C and Its Derivatives on Collagen Synthesis and Cross-Linking by Normal Human Fibroblasts. View Source

17. Journal of Pharmaceutical Sciences (2015) — Badhe RV, Bijukumar D, Chejara DR, et al. Microneedle-Mediated Delivery of Copper Peptide Through Skin. View Source

18. Inflammation Research (2010) — Hostynek JJ, Dreher F, Maibach HI. Human Skin Retention and Penetration of a Copper Tripeptide In Vitro as Function of Skin Layer Towards Anti-Inflammatory Therapy. View Source

⚠️ Disclaimer: This page is provided for educational and informational purposes only and does not constitute medical advice, diagnosis, or treatment recommendations. Glow BPC-70 is sold exclusively as a research compound and has not been approved by the FDA for human consumption. All information is derived from published peer-reviewed literature concerning the individual component peptides (GHK-Cu, BPC-157). The specific proprietary blend has not been evaluated in independent clinical trials. Research must comply with all applicable laws, regulations, and institutional guidelines.

Purchase Glow BPC-70 for Research →